HIND

Business Context and Reporting Period

This summary covers the Form 10-Q for ReShape Lifesciences Inc. (trading symbol: RSLS), which is in the process of merging with Vyome Therapeutics, Inc. to become Vyome Holdings, Inc. The reporting period ended June 30, 2025. The Company is a physician-led weight-loss solutions provider currently facing significant headwinds from GLP-1 pharmaceuticals. Management has expressed substantial doubt about the Company's ability to continue as a going concern without the successful completion of the pending merger and asset sale.

Key Financial Metrics

Note: The Net Loss for the six months ended June 30, 2025, was significantly reduced by a non-cash gain of $3.66 million related to changes in the fair value of liability warrants.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 36.8% year-over-year for the quarter and 39.8% for the six-month period. Management attributes this primarily to competition from GLP-1 pharmaceuticals and reduced sales volume.
• Transaction Costs: Transaction costs related to the pending merger and asset sale increased significantly, rising from $0.21 million to $0.71 million for the quarter, and from $0.33 million to $1.04 million for the six-month period.
• Financing Activity: The Company raised approximately $10.9 million in net proceeds during the first half of 2025 through public offerings and an "at-the-market" (ATM) offering. This contrasts with the prior year period which saw minimal financing activity.
• Debt Repayment: The Company repaid a $0.81 million convertible note in full during the period, resulting in zero current debt as of June 30, 2025.

Outlook, Risks, and Management Commentary

• Pending Merger and Asset Sale: The Company is executing a merger with Vyome Therapeutics and an asset sale to Biorad (Ninjour Health International Limited). Stockholders approved these proposals in July 2025. The combined entity will focus on Vyome's immuno-inflammatory assets.
• Liquidity and Going Concern: Despite recent capital raises, management states that available cash resources may not be sufficient to fund operations for more than 12 months. This raises substantial doubt about the Company's ability to continue as a going concern absent the completion of the merger.
• Internal Control Weaknesses: The Company identified material weaknesses in internal controls over financial reporting, citing insufficient accounting resources, lack of management review, and segregation of duties conflicts. Remediation plans are underway.
• Legal Proceedings: The Company is a defendant in a proposed class action lawsuit in Canada regarding the Lap-Band device. Management does not believe liability is probable or estimable at this time.
• Operational Shifts: The Company has paused clinical trials for the Diabetes Bloc-Stim Neuromodulation device to preserve cash and reduced marketing expenditures.

Investor Verification Checklist

• Merger Closing Status: Verify the final closing date and conditions for the Vyome merger and Biorad asset sale, as the Company's future operations depend entirely on these transactions.
• Cash Runway: Confirm the current cash burn rate and whether additional financing is required before the merger closes, given the "substantial doubt" disclosure.
• Transaction Cost Impact: Monitor the remaining transaction costs associated with the merger, which have already consumed a significant portion of operating expenses.
• Internal Control Remediation: Review future filings for updates on the remediation of material weaknesses in financial reporting controls.
• Legal Exposure: Track the status of the Canadian class action lawsuit regarding the Lap-Band device to assess potential future liabilities.